> Skip repeated content
Photo of Dr. Ayturk

Ugur Ayturk, PhD


Phone Icon Image
Photo of Dr. Ayturk

Ugur Ayturk, PhD


Phone Icon Image

Dr. Ugur Ayturk joined Hospital for Special Surgery in Fall 2017 as an Assistant Scientist. Prior to coming to HSS, Dr. Ayturk was an Instructor in Orthopaedic Surgery at Boston Children’s Hospital and Harvard Medical School. He completed his PhD work at Colorado State University, and trained as a postdoctoral fellow in Dr. Matthew Warman’s lab in the Department of Orthopaedic Surgery at Boston Children’s Hospital.

Back in the Game Patient Stories

Research Description

Our goal is to develop an improved understanding of osteoblasts, and use this knowledge to enhance their bone forming capabilities. We are specifically interested in how osteoblasts differentiate from mesenchymal precursors, and how their activities and molecular identity are altered under genetic and environmental perturbations. We use a multitude of approaches including transcriptional profiling (bulk and single cell RNA-seq), genetic modification of mouse models and primary cell culture in our investigations.

We currently have postdoctoral and technician positions available. Interested candidates with wet- and/or dry-lab experience should send their CV with a brief description of interests and list of references to ayturku@hss.edu.

Industry Relationships

One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.

As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.

As of July 02, 2018, Dr. Ayturk reported no financial interest relationships with healthcare industry.

By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.

Selected Publications

Tafaj O, Hann S, Ayturk U, Warman ML, Jueppner H. Mice maintain predominantly maternal Gαs expression throughout life in brown fat tissue (BAT), but not other tissues. Bone, 103: 177-187, 2017.

Couto JA, Ayturk UM, Konczyk DJ, Goss JA, Huang AY, Hann S, Reeve JL, Liang MG, Bischoff J, Warman ML, Greene AK. A Somatic GNA11 Mutation is Associated with Extremity Capillary Malformation and Overgrowth. Angiogenesis, 20: 303-306, 2017.

Sieker JT, Ayturk UM, Proffen BL, Murray MM. Immediate Administration of Intraarticular Triamcinolone Acetonide after Joint Injury Modulates Molecular Outcomes Associated with Early Synovitis. Arthritis and Rheumatology, 68: 1637-47, 2016.

Ayturk UM*, Couto JA*, Hann S, Mulliken JB, Williams KL, Huang Y, Fishman SJ, Boyd TK, Kozakewich HPW, Bischoff J, Greene AK, Warman ML. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. American Journal of Human Genetics, 98: 789-795, 2016 (*Equal contribution by the authors).

Hill A*, Waller KA*, Cui Y, Allen JM, Smits P, Zhang LX, Ayturk UM, Zurakowski D, Warman ML, Jay GD. Lubricin restoration in the context of deficiency. Arthritis and Rheumatology, 67: 1261-73, 2015 (*Equal contribution by the authors).

Kozhemyakina E, Zhang M, Ionescu A, Ayturk UM, Ono N, Kobayashi A, Kronenberg H, Warman ML, Lassar AB. Identification of a Prg4-positive articular cartilage progenitor cell population. Arthritis and Rheumatology, 67: 1261-73, 2015.

Bennike T, Ayturk U, Haslauer CM, Froehlich JW, Proffen BL, Barnaby O, Birkelund S, Murray MM, Warman ML, Stensballe A, Steen H. A normative study of the synovial fluid proteome from healthy porcine knee joints. Journal of Proteome Research, 13: 4377-87, 2014.

Jacobsen CM, Barber LA, Ayturk UM, Roberts HJ, Deal LE, Schwartz MA, Weis M, Eyre D, Zurakowski D, Robling AG, Warman ML. Targeting the LRP5 pathway improves bone properties in a mouse model of Osteogenesis Imperfecta. Journal of Bone and Mineral Research, 28: 2081-93, 2014.

Bowen ME, Ayturk UM, Kurek KC, Yang W, Warman ML. SHP2 regulates chondrocyte terminal differentiation, growth plate architecture, and skeletal cell fates. PLOS Genetics, 10(5):e1004364, 2014.

Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Pazsty C, Warman ML and Robling AG. Sclerostin inhibition reverses skeletal fragility in an Lrp5 deficient mouse model of OPPG syndrome. Science Translational Medicine, 5:211ra518, 2013.

Ayturk UM, Jacobsen CM, Christodoulou DC, Gorham J, Seidman JG, Seidman CE, Robling AG and Warman ML. An RNA-seq Protocol to Identify mRNA Expression Changes in Mouse Diaphyseal Bone: Applications in Mice with Bone Property Altering Lrp5 Mutations. Journal of Bone and Mineral Research, 28: 2081-93, 2013.

Appointments

Assistant Scientist, Musculoskeletal Integrity Program, Hospital for Special Surgery